During the past decade, Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 40 clinical trials were completed, i.e. on average, 78.4% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 18 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY" #1 sponsor was "VA Office of Research and Development" with 37 trials, followed by "Eastern Cooperative Oncology Group" with 17 trials sponsored, "US Department of Veterans Affairs" with 17 trials sponsored, "National Cancer Institute (NCI)" with 13 trials sponsored and "VA New York Harbor Healthcare System" with 13 trials sponsored. Other sponsors include 39 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY" #1 collaborator was "National Cancer Institute (NCI)" with 26 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 6 trials as a collaborator, "VA New York Harbor Healthcare System" with 5 trials as a collaborator, "Cancer and Leukemia Group B" with 3 trials as a collaborator and "Eastern Cooperative Oncology Group" with 3 trials as a collaborator. Other collaborators include 107 different institutions and companies that were collaborators in the rest 101 trials.

According to Clinical.Site data, the most researched conditions in "Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY" are "Colorectal Cancer" (7 trials), "Coronary Artery Disease" (5 trials), "Heart Failure" (4 trials), "Hypertension" (4 trials) and "Prostate Cancer" (4 trials). Many other conditions were trialed in "Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY" in a lesser frequency.

Most popular intervention types in "Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY" are "Drug" (77 trials), "Other" (27 trials), "Behavioral" (25 trials), "Biological" (16 trials) and "Procedure" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Laboratory Biomarker Analysis" (9 trials), "Cisplatin" (5 trials), "Bevacizumab" (4 trials) and "Placebo Administration" (4 trials). Other intervention names were less common.

The vast majority of trials in "Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY" are 128 trials for "All" genders, 6 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are 38 active trials in "Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY". 3 are not yet recruiting, 14 are recruiting, 20 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 85 completed trials in Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, 4 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 40 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 15 trials, and there were also 39 trials that are defined as “Not Applicable".